Aphria (NYSE:APHA) posted its earnings results on Thursday. The company reported $0.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.10, Briefing.com reports. The company had revenue of $128.60 million for the quarter, compared to analyst estimates of $99.26 million. The business’s quarterly revenue was up 971.7% on a year-over-year basis.
Aphria stock opened at $7.33 on Friday. The firm has a market cap of $1.31 billion, a price-to-earnings ratio of -66.64 and a beta of 3.07. Aphria has a 1 year low of $3.75 and a 1 year high of $16.86. The stock’s 50-day moving average is $6.49.
APHA has been the subject of several analyst reports. Clarus Securities initiated coverage on Aphria in a research report on Tuesday, April 16th. They set a “buy” rating and a $22.75 target price for the company. Jefferies Financial Group initiated coverage on Aphria in a research report on Friday, May 24th. They set a “buy” rating and a $11.00 target price for the company. CIBC lowered Aphria from a “neutral” rating to a “sector underperform” rating in a research report on Friday, July 26th. Zacks Investment Research upgraded Aphria from a “strong sell” rating to a “hold” rating in a research report on Friday, May 10th. Finally, ValuEngine upgraded Aphria from a “hold” rating to a “buy” rating in a research report on Thursday. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $14.75.
Aphria Inc produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc is headquartered in Leamington, Canada.
Further Reading: Rule of 72
Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.